Last Updated: June 22, 2026

MILNACIPRAN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


DrugPatentWatch® Litigation and Generic Entry Outlook for Milnacipran

A generic version of MILNACIPRAN was approved as milnacipran hydrochloride by BRECKENRIDGE on January 27th, 2016.

  Start Trial

AI Deep Research
Ask!
Questions you can ask:
  • What is the 5 year forecast for MILNACIPRAN?
  • What are the global sales for MILNACIPRAN?
  • What is Average Wholesale Price for MILNACIPRAN?
Summary for MILNACIPRAN
US Patents:0
Applicants:3
NDAs:3
DailyMed Link:MILNACIPRAN at DailyMed
Drug patent expirations by year for MILNACIPRAN

US Patents and Regulatory Information for MILNACIPRAN

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Amneal Pharms MILNACIPRAN HYDROCHLORIDE milnacipran hydrochloride TABLET;ORAL 205081-001 Apr 22, 2016 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Breckenridge MILNACIPRAN HYDROCHLORIDE milnacipran hydrochloride TABLET;ORAL 205071-003 Jan 27, 2016 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Amneal Pharms MILNACIPRAN HYDROCHLORIDE milnacipran hydrochloride TABLET;ORAL 205081-004 Apr 22, 2016 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Hetero Labs Ltd V MILNACIPRAN HYDROCHLORIDE milnacipran hydrochloride TABLET;ORAL 205147-004 Oct 3, 2024 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Breckenridge MILNACIPRAN HYDROCHLORIDE milnacipran hydrochloride TABLET;ORAL 205071-004 Jan 27, 2016 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Amneal Pharms MILNACIPRAN HYDROCHLORIDE milnacipran hydrochloride TABLET;ORAL 205081-002 Apr 22, 2016 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Subscribe to access the full database, or Start Trial

DrugChatter Q&A for MILNACIPRAN
Milnacipran savella availability countries approval status 2024?

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links